Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by High Dose Rifampicin Rif

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT01571752Completed

Health Outcomes by Neighborhood - Baltimore

NCT04521803Phase 2Completed

High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

Showing all 2 trials

Research Network

Common Treatments

  • High Dose Rifampicin Rif1

Active Sponsors

  • University of Cape Town1
  • National Institute on Drug Abuse (NIDA)1

Top Investigators

Related Conditions

  • Stigma1
  • Social Networks1
  • Tuberculous Pericarditis1
  • Drug Abusedependence1
  • Activity Space1

Activity Timeline